<table border="0" cellpadding="2" cellspacing="1" id="i42d7aee2-c42d-4fbf-8b64-c3730ebbdaa3" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 19: Summary of Virologic Failures<sup>a</sup> at Week 96 in Study AI424-089: Comparison of Ritonavir Boosted REYATAZ vs. Unboosted REYATAZ: Randomized Patients</caption>
<colgroup>
<col width="54%"></col>
<col width="23%"></col>
<col width="23%"></col>
</colgroup>
<thead>
<tr>
<th rowspan="2" stylecode="Toprule Botrule"> </th>
<th align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">REYATAZ 300 mg +<br/>ritonavir 100 mg </content>
</th>
<th align="center" stylecode="Toprule" valign="top">
<content stylecode="bold">REYATAZ 400 mg</content>
</th>
</tr>
<tr>
<th align="center" stylecode="Botrule">
<content stylecode="bold">(n=95)</content>
</th>
<th align="center" stylecode="Botrule">
<content stylecode="bold">(n=105) </content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="3" stylecode="Toprule">
<sup>a</sup> Virologic failure includes patients who were never suppressed through Week 96 and on study at
Week 96, had virologic rebound or discontinued due to insufficient viral load response.</td>
</tr>
<tr>
<td colspan="3">
<sup>b</sup> Percentage of Virologic Failure
Isolates with genotypic and phenotypic data. </td>
</tr>
<tr>
<td colspan="3" stylecode="Botrule">
<sup>c</sup> Mixture of I50I/L emerged in 2 other ATV 400 mg-treated patients. Neither isolate was phenotypically resistant to ATV.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td>Virologic Failure (≥50 copies/mL) at Week 96  </td>
<td align="center">15 (16%)</td>
<td align="center">34 (32%)</td>
</tr>
<tr>
<td>Virologic Failure with Genotypes and Phenotypes Data</td>
<td align="center">5</td>
<td align="center">17</td>
</tr>
<tr>
<td>Virologic Failure Isolates with ATV-resistance at Week 96 </td>
<td align="center">0/5 (0%)<sup>b</sup>
</td>
<td align="center">4/17 (24%)<sup>b</sup>
</td>
</tr>
<tr>
<td>Virologic Failure Isolates with I50L Emergence at Week 96<sup>c</sup>
</td>
<td align="center">0/5 (0%)<sup>b</sup>
</td>
<td align="center">2/17 (12%)<sup>b</sup>
</td>
</tr>
<tr>
<td>Virologic Failure Isolates with Lamivudine Resistance at Week 96</td>
<td align="center">2/5 (40%)<sup>b</sup>
</td>
<td align="center">11/17 (65%)<sup>b</sup>
</td>
</tr>
</tbody>
</table>